Audience Break-Down
350+
Attendees
60+
Leading Top Speakers
20+
Dedicated Networking Hours
50%
In-House Counsel
Highlights Coming Up
- Skinny Label Case Law Review: Understand the Latest Strategies and Updates from Amarin Pharma v. Hikma
- BPCIA Litigation Review: Discover the latest in biologics litigation strategy
- Safe Harbor & Bolar Exemption: Review safe harbor and bolar exemption developments and strategy
- Share your views at our Roundtables: Join our roundtable discussions, convening 15-20 practitioners for a deep-dive into a specialist topic
- Venue selection and cross-border strategy: Review the strategic benefits of venues like the PTAB, ITC, and the UPC
Build Connections and Benchmark Alongside:
In-House Counsels in Pharma and Biotech
- General Counsel
- Global Head of IP
- Head of Patent Litigation
- VP-Intellectual Property
- Head of Legal/Legal Affairs
- Assistant General Counsel-IP
- Head of Global IP Strategy
- IP and Portfolio Management
- Patent Counsel
- Patent Litigation Counsel
- Divisional Counsel
Outside Counsels with Expertise in:
- Intellectual Property and Patent Law
- Hatch-Waxman Litigation
- Life Sciences
- Trade Secrets
- US Patent Law
- European Patent Law
